Πρόσφατες ενημερώσεις
- Blinatumomab (BLINCYTO) Prescribing Information | Hong Kong Dengyue MedicineBLINCYTO® is the world’s first approved BiTE® immuno-oncology therapy, targeting the CD19 surface antigen on B cells. BiTE® molecules help the immune system detect and target malignant cells by bringing T cells—a type of white blood cell capable of killing cells recognized as threats—into contact with cancer cells. By positioning T cells near cancer cells, they can...0 Σχόλια 0 Μοιράστηκε 68 ViewsΠαρακαλούμε συνδέσου στην Κοινότητά μας για να δηλώσεις τι σου αρέσει, να σχολιάσεις και να μοιραστείς με τους φίλους σου!
και άλλες ιστορίες
DengYue Medicine (DengYueMed/Hong Kong Dengyue Pharmaceutical Limited), founded in 2019, is located in Hong Kong SAR. DengYue is licensed by the Department of Health of Hong Kong to take photos of pharmaceutical import and export wholesalers, specializing in the import and export of new and specialty drugs as well as isolated drugs in the field of major chronic diseases.